当前位置: 首页 > 期刊 > 《中国医学创新》 > 2019年第5期
编号:13391706
鼠神经生长因子结合盐酸川芎嗪治疗IFP的可行性及安全性(1)
http://www.100md.com 2019年2月15日 《中国医学创新》 2019年第5期
     【摘要】 目的:探討鼠神经生长因子结合盐酸川芎嗪在特发性面神经麻痹(idiopathic facial paralysis,IFP)治疗中的可行性及安全性。方法:选择2014年6月-2017年6月本院收治的45例IFP患者为研究对象,按照随机数字表法将患者分为试验组(23例)及对照组(22例)。对照组给予地塞米松、阿昔洛韦等常规药物治疗,试验组在此基础上应用鼠神经生长因子联合盐酸川芎嗪治疗,通过观察两组的H-B分级、中医病证诊断评估疗效、面神经的传导速度改善情况及安全性相关不良反应的差异,分析其临床意义及影响。结果:治疗前,两组H-B面神经功能分级比较,差异均无统计学意义(P>0.05),治疗后,两组比较差异有统计学意义(P<0.05)。试验组的组H-B分级法、中医病证诊断的总有效率均高于对照组,差异均有统计学意义(P<0.05)。治疗后,试验组RI潜伏期显著短于治疗前,且试验组短于对照组,差异均有统计学意义(P<0.05)。结论:鼠神经生长因子结合盐酸川芎嗪治疗IFP效果肯定,无不良反应,能更好改善患者症状,安全可行,值得临床推广应用。

    【关键词】 鼠神经生长因子; 盐酸川芎嗪; IFP; 可行性; 安全性

    【Abstract】 Objective:To explore the feasibility and safety of Rat Nerve Growth Factor combined with Ligustrazine Hydrochloride in the treatment of idiopathic facial paralysis(IFP).Method:45 patients with idiopathic facial paralysis in our hospital from June 2014 to June 2017 were selected as subjects and randomly divided into experimental group(23 cases)and control group(22 cases).The control group was given conventional drugs such as dexamethasone and acyclovir.The experimental group applied Rat Nerve Growth Factor in combination with Ligustrazine Hydrochloride on the basis of this.By observing the difference between H-B classification method,TCM syndrome diagnosis standard,facial nerve conduction velocity improvement and safety-related adverse reactions under the two treatment modes,the clinical significance and impact were analyzed.Result:Before treatment,there was no significant difference in H-B facial nerve function grading between the two groups(P>0.05);after treatment,there was significant difference between the two groups(P<0.05).The total effective rate of H-B grading method and TCM syndrome diagnosis in the experimental group were higher than those in the control group,with statistically significant differences(P<0.05).After treatment,RI incubation period of the experimental group was significantly shorter than that before treatment,and the experimental group was shorter than that of the control group,with statistically significant differences(P<0.05).Conclusion:Rat Nerve Growth Factor combined with Ligustrazine Hydrochloride in the treatment of IFP has positive effect and no adverse reactions,can better improve the symptoms of patients,safe and feasible,it is worthy of clinical application.

    【Key words】 Mouse Nerve Growth Factor; Tetramethylpyrazine Hydrochloride; Idiopathic facial paralysis; Feasibility; Safety

    First-author’s address:Jiexi People’s Hospital,Jiexi 515400,China, 百拇医药(刘宇凡)
1 2 3 4下一页